Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours

G. H. Hall, L. W. Turnbull, I. Richmond, L. Helboe, S. L. Atkin

Research output: Contribution to journalArticle

19 Citations (Scopus)


Somatostatin has been identified as having anti-proliferative, anti-angiogenic and pro-apoptotic actions in many tumour systems, and these effects are mediated through a family of five transmembrane G-protein coupled SRIF receptors. Ovarian cancer is the commonest gynaecological malignancy in the UK and maintenance therapy is urgently required. Native somatostatin expression and its receptors sst1, 2, 3 and 5 were studied with immunohistochemistry in 63 malignant and 35 benign ovarian tumours of various histological types. Fifty-seven out of 63 (90%) of malignant and 26/35 (74%) benign tumours expressed somatostatin. Receptors sst1, 2, 3 and 5 were expressed variably in epithelial, vascular and stromal compartments for both benign and malignant tumours. Somatostatin was found to correlate significantly with stromal sst1 (P=0.008), epithelial sst1 (P < 0.001), stromal sst2 (P=0.019), vascular sst2 (P=0.026), epithelial sst3 (P=0.026), stromal sst5 (P=0.013) and vascular SSt5 (P=0.038). Increased expression of native somatostatin correlating with somatostatin receptors in malignant ovarian tumours raises the possibility that either synthetic somatostatin antagonists or receptor agonists may have therapeutic potential.

Original languageEnglish
Pages (from-to)86-90
Number of pages5
JournalBritish Journal of Cancer
Issue number1
Publication statusPublished - 1 Jan 2002


  • Angiogenesis
  • Immunohistochemistry
  • Ovarian cancer
  • Somatostatin
  • Somatostatin receptors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours'. Together they form a unique fingerprint.

  • Cite this